Hemodynamic results of perorally administered converting enzyme inhibitors in congestive heart failure
- PMID: 6089312
Hemodynamic results of perorally administered converting enzyme inhibitors in congestive heart failure
Abstract
The acute hemodynamic response to captopril (8 patients) and enalapril (8 patients) was evaluated in congestive heart failure patients in NYHA functional class III. All patients had a history of congestive heart failure for more than six months. The results show marked interindividual variations but average values for cardiac output increase and decrease in filling pressures agree with findings in the literature. 6 patients in the captopril group and five in the enalapril group were started on maintenance therapy. One patient in the captopril group deteriorated and underwent a successful heart transplantation and one patient in the enalapril group returned with arrhythmias and hypertension (probably not drug-related) after 48 h of therapy. Our data indicate that activation of the renin-angiotensin system through excessive administration of loop-diuretics is associated with a risk of hypovolemia and thus drug-induced hypotension that deserves special attention when considering converting enzyme inhibitor therapy in congestive heart failure.
Similar articles
-
Hemodynamic Results of Perorally Administered Converting Enzme Inhibitors in Congestive Heart Failure.Scand J Urol Nephrol. 1984 Jul;18(sup79):129-132. doi: 10.1080/00365599.1984.11783731. Scand J Urol Nephrol. 1984. PMID: 27785996
-
Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.Fed Proc. 1984 Apr;43(5):1314-21. Fed Proc. 1984. PMID: 6323221 Review.
-
Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.Clin Pharm. 1985 Jan-Feb;4(1):27-40. Clin Pharm. 1985. PMID: 2982541 Review.
-
Role of angiotensin-converting enzyme inhibitors in congestive heart failure.Heart Lung. 1990 Sep;19(5 Pt 1):505-11. Heart Lung. 1990. PMID: 2211159 Review.
-
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.Prescrire Int. 2005 Oct;14(79):180-6. Prescrire Int. 2005. PMID: 16285075
Cited by
-
Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.Br J Clin Pharmacol. 1991 Jan;31(1):1-13. doi: 10.1111/j.1365-2125.1991.tb03851.x. Br J Clin Pharmacol. 1991. PMID: 1849731 Free PMC article. Review.
-
Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.Drugs. 1986 Mar;31(3):198-248. doi: 10.2165/00003495-198631030-00002. Drugs. 1986. PMID: 3011386 Review.
-
The response to the first dose of an angiotensin converting enzyme inhibitor in uncomplicated hypertension--a placebo controlled study utilising ambulatory blood pressure recording.Br J Clin Pharmacol. 1991 Sep;32(3):393-8. doi: 10.1111/j.1365-2125.1991.tb03918.x. Br J Clin Pharmacol. 1991. PMID: 1777377 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Medical